Drug intelligence / Profile preview

BTN166

Development stage: Preclinical
Lead developer: BioNTech
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BTN166 is an mRNA vaccine candidate developed by BioNTech. It is specifically designed to target mpox, a viral disease. The development of BTN166 is supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), with an initial allocation of up to $90 million to advance the candidate in response to the 2022 mpox outbreak. BioNTech is also scaling up its manufacturing facility in Kigali, Rwanda, which will contribute to the production of this vaccine.

Beyond the preview

Go deeper on BTN166.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTN166.